EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trial

Yan Zhao iD, Litao Zhang, Liming Wu, Bin Yang, Jinyan Wang, Yumei Li, Jingyi Li, Qingchun Diao, Qing Sun, Xiaohong Zhu, Xiaoyong Man iD, Lihua Wang und 12 weitere

Allergy · 2025-05 · 80 (5) · 1348-1357

DOI: 10.1111/all.16368 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Allergy, online erschienen am 25.10.2024. Verfasst von Yan Zhao und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Keymed Biosciences (Chengdu) Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Management of moderate‐to‐severe atopic dermatitis (AD) needs long‐term therapy. Stapokibart is a humanized monoclonal antibody targeting interleukin‐4 receptor α subunit (IL‐4Rα), a shared receptor for IL‐4 and IL‐13 which are key pathogenic drivers of AD. In a pivotal phase 3 trial (NCT05265923), significant higher proportions of adult AD patients receiving stapokibart than placebo achieved ≥75% improvement from baseline in Eczema Area and Severity Index (EASI‐75; 66.9% vs. 25.8%) and Investigator's Global Assessment (IGA) score of 0/1 with ≥2‐point reduction (44.2% vs. 16.1%) at Week 16. Herein, we report long‐term (52 weeks) efficacy and safety of stapokibart from this trial.

Methods

After 16‐week double‐blind treatment completed, patients in both stapokibart and placebo groups entered a 36‐week maintenance treatment period and received stapokibart 300 mg every 2 weeks. Concomitant use of topical medications for AD was permitted throughout the maintenance period.

Results

Of 476 patients entering maintenance period, 430 completed the treatment. At Week 52, EASI‐75 was achieved in 92.5% of patients continuing stapokibart and 88.7% of those switching from placebo to stapokibart, respectively; an IGA score of 0 or 1 with a ≥2‐point reduction was achieved in 67.3% and 64.2% of patients, respectively; a ≥4‐point reduction in weekly average of daily Peak Pruritus Numerical Rating Scale (PP‐NRS) was achieved in 67.3% and 60.5% of patients, respectively. Over the 52‐week treatment period, 88.1% of patients reported treatment‐emergent adverse events, most were mild or moderate.

Conclusion

Long‐term treatment with stapokibart demonstrated a sustained efficacy and favorable safety profile in adults with moderate‐to‐severe AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedHumansFemaleMaleAdultTreatment OutcomeSeverity of Illness IndexMiddle AgedDouble-Blind MethodYoung Adult

Stichwörter der Autor:innen

adultslong‐term efficacymoderate‐to‐severe atopic dermatitisstapokibart

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Peking University People's Hospital, Beijing, China.
  • Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
  • Department of Dermatology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
  • Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Dermatology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
  • Department of Dermatology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.

ORCID-Profile: Yan Zhao, Xiaoyong Man, Linfeng Li, Jianzhong Zhang

Förderung

  • Keymed Biosciences (Chengdu) Co., Ltd

Zitieren

APA

Zhao, Y., Zhang, L., Wu, L., Yang, B., Wang, J., Li, Y., Li, J., Diao, Q., Sun, Q., Zhu, X., Man, X., Wang, L., Li, L., Feng, Y., Zeng, H., Cai, T., Ren, H., Lu, J., Lu, Q., …, & Zhang, J. (2025). Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trial. Allergy, 80(5), 1348-1357. https://doi.org/10.1111/all.16368

Vancouver

Zhao Y, Zhang L, Wu L, Yang B, Wang J, Li Y, et al. Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trial. Allergy. 2025;80(5):1348-1357. doi:10.1111/all.16368

BibTeX
@article{Zhao2025,
  author = {Zhao, Yan and Zhang, Litao and Wu, Liming and Yang, Bin and Wang, Jinyan and Li, Yumei and Li, Jingyi and Diao, Qingchun and Sun, Qing and Zhu, Xiaohong and Man, Xiaoyong and Wang, Lihua and Li, Linfeng and Feng, Yanyan and Zeng, Huiming and Cai, Tao and Ren, Hong and Lu, Jianyun and Lu, Qianjin and Tao, Xiaohua and Xiao, Rong and Ji, Chao and Li, Fuqiu and Zhang, Jianzhong},
  title = {Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trial},
  journal = {Allergy},
  year = {2025},
  volume = {80},
  number = {5},
  pages = {1348--1357},
  doi = {10.1111/all.16368}
}
Kostenlos starten →